-
1 Comment
ARCA biopharma, Inc is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
ARCA biopharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 318.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 159.3% to $-3M since the same quarter in the previous year.
Based on the above factors, ARCA biopharma, Inc gets an overall score of 1/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | US00211Y5069 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Dividend Yield | 0.0% |
|---|---|
| Beta | 0.9 |
| Market Cap | 3M |
| PE Ratio | None |
| Target Price | None |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HQ10.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
